Clinical Trials Browser

Phase 2 × INDUSTRY × sacituzumab govitecan × Clear all

NCT05633667 2026-06-01

VELOCITY-Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03964727 2026-04-28

TROPiCS-03

Phase 2 Active not recruiting

227 enrolled 31 charts

Neoplasm Metastasis

NCT05327530 2026-04-24

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT05186974 2026-02-11

EVOKE-02

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

Neoplasms

NCT02161679 2021-08-19

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 2 Withdrawn

Triple Negative Breast Neoplasms